NYMC Faculty Publications
Dual Neutralization of Both Interleukin 17A and Interleukin 17F with Bimekizumab in Patients with Psoriasis: Results from BE ABLE 1, 12-Week Randomized, Double-Blinded, Placebo-Controlled Phase 2b Trial
DOI
10.1016/j.jaad.2018.03.037
Journal Title
Journal of the American Academy of Dermatology
First Page
277
Last Page
286
Document Type
Article
Publication Date
8-1-2018
Department
Dermatology
Abstract
BACKGROUND: Neutralizing interleukin (IL) 17F in addition to IL-17A might provide a more complete and specific approach to inhibiting inflammation. OBJECTIVE: Assess the efficacy and safety of bimekizumab, a monoclonal antibody that potently and selectively neutralizes IL-17A and IL-17F, in patients with moderate-to-severe plaque psoriasis. METHODS: Double-blinded, placebo-controlled phase 2b study (NCT02905006). Patients (randomized 1:1:1:1:1:1) received subcutaneous bimekizumab every 4 weeks at doses of 64 mg, 160 mg, 160 mg with 320 mg loading dose, 320 mg, 480 mg, or placebo. Primary endpoint was >/=90% reduction in Psoriasis Area Severity Index (PASI90) at week 12. RESULTS: There was a significant (P < .0001) dose-dependent response for PASI90 (week 12); more patients achieved PASI90 in the bimekizumab groups (46.2%-79.1%) than patients in the placebo group (0%; P < .0001 all doses). Across all doses, there were significant improvements from baseline for all secondary endpoints (PASI90 week 8, PASI75 week 12, PASI100 week 12, and Investigators Global Assessment clear or almost clear weeks 8 and 12; P
Recommended Citation
Papp, K., Merola, J., Gottlieb, A., Griffiths, C., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2018). Dual Neutralization of Both Interleukin 17A and Interleukin 17F with Bimekizumab in Patients with Psoriasis: Results from BE ABLE 1, 12-Week Randomized, Double-Blinded, Placebo-Controlled Phase 2b Trial. Journal of the American Academy of Dermatology, 79 (2), 277-286. https://doi.org/10.1016/j.jaad.2018.03.037
